Sorin invests $5.4M in percutaneous mitral valve developer

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Sorin Group has made a minority investment with option-to-buy in HighLife, an early-stage company focused on the development of a transcatheter mitral valve replacement system to treat patients with mitral regurgitation.

HighLife, located in Paris, was co-founded in 2010 by Georg Börtlein, who was a co-founder and chief operating officer at CoreValve, a developer of transcatheter aortic valve replacement products.

Sorin's EUR4.2 million ($5.44 million U.S.) initial investment will finance ongoing product development and clinical testing of the technology. Under the terms of the agreement, Milan, Italy-based Sorin also has acquired an exclusive option to acquire the company in the future. This investment is meant to complement the recently announced investment in Cardiosolutions, which is developing a percutaneous mitral repair system, according to Sorin.